For autologous stem cell transplantation, it is common practice to infuse at least 2 ؋ 10 6 /kg CD34 ؉ cells to ensure rapid engraftment. However it was recently claimed that increasing the threshold to 5؋10 ؉ cells we found a significant reduction in the median number of days with fever (1 vs 3.5 days, P ‫؍‬ 0.0025), incidence of fever (78.8 vs 92.1%, P ‫؍‬ 0.032) as well as duration of antibiotic treatment (7 vs 10 days, P ‫؍‬ 0.038). This was paralleled by a faster neutrophil recovery to 0.5 ؋ 10 9 /l (9 vs 10 days, P ‫؍‬ 0.047). There was no significant difference in the number of platelet or red cell transfusions between the two groups. We conclude that transplantation with a stem cell dose of at least 5 ؋ 10 6 /kg CD34 ؉ cells reduces infectious complications and should thereby increase the safety of this type of therapy while reducing duration (and cost) of antibiotic therapy. The transplantation threshold should thus not remain at 2 ؋ 10 6 /kg particularly in patients with a good stem cell mobilisation capacity.
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Patients and methods

Patients
For this analysis, data from 127 consecutive autologous transplants performed between 1992 and 1998 in our centre were included. The median age was 43 years, ranging from 18 to 69 years. Diagnoses were non-Hodgkin's lymphoma (n ϭ 61), Hodgkin's disease (n ϭ 24), breast cancer (n ϭ 18), multiple myeloma (n ϭ 18), germ cell tumours (n ϭ 2), AML (n ϭ 2), ALL (n ϭ 1) and non-small cell lung cancer (n ϭ 1) (see Table 1 ). Thirty-nine patients received high-dose chemotherapy as part of their initial therapy, 25 had been refractory to first-line treatment, 52 were in first relapse and 11 were in second relapse or more.
Stem cell mobilisation and collection
To mobilise stem cells 57 patients received G-CSF (Filgrastim; Amgen, Munich, Germany) at a dose of 5-10 g/kg/day intravenously or subcutaneously and underwent one to four leukaphereses (Baxter CS 3000 or Cobe Spectra, Unterschleissheim, Germany) starting from day 5 after initiation of G-CSF. Another 70 patients were leukapheresed after receiving chemotherapy followed by subcutaneous G-CSF at 5-10 g/kg/day. Twenty patients were transplanted with CD34 ϩ selected PBSC grafts using the Ceprate SC device (CellPro, Munich, Germany).
Flow cytometry
The number of CD34 ϩ cells in leukapheresis products and bone marrow harvests was determined according to the protocol proposed by Sienna et al. 4 50 l of cell suspension was incubated with 10 l of a phytoerythrin (PE)-conjugated anti-CD34 antibody or IgG1 control antibody (all Becton Dickinson) for 20 min, followed by erythrocyte lysis (FACS lysis solution, Becton Dickinson) and analysis on a flow cytometer (FACScan or FACS Calibur, both Becton Dickinson, Heidelberg, Germany). CD34 ϩ cells were determined by bright CD34-PE fluorescence and low side scatter, and positive counts with control antibody were subtracted. (carboplatin 2200 mg/m 2 , etoposide 1800 mg/m 2 , cyclophosphamide 6400 mg/m 2 , n ϭ 2) or BUCY (busulphan 40 mg/kg, cyclophosphamide 120 mg/kg, n ϭ 1).
Supportive care
All patients were treated in isolation rooms under sterile conditions from the day before transplantation until neutrophil engraftment and received daily oral prophylactic treatment with trimethoprim (160 mg), sulfamethoxazole (800 mg), tobramycin (320 mg) and fluconazole (200 mg) and nystatin mouth washes (3 000 000 IU). From day 1 after transplantation G-CSF was administered at a dose of 10 g/kg until leucocyte recovery to Ͼ10 ϫ 10 9 /l. This was then reduced to 5 g/kg for 2 days and stopped thereafter. Packed red blood cells were administered to maintain the haemoglobin above 80 g/l, and platelets were transfused to maintain platelet counts above 40 ϫ 10 9 /l. All blood products were irradiated with 30 Gy. Empirical antibiotic treatment was initiated when the temperature rose above 38°C on two separate occasions. This comprised intravenous tobramycin (3-5 mg/kg/day) and ceftazidim (3 ϫ 2 g/day). When fever persisted for 72 h vancomycin (2 ϫ 1 g/day) was added. After 5 days of fever, amphotericin B (0.7-1 mg/kg) was given. All patients had a central venous line inserted the day before transplantation which was changed when fever persisted for more than 5 days or the insertion site became infected.
Statistics
All results are given as median and range unless stated otherwise. Comparisons between different groups were made by the non-parametric Mann-Whitney U test. Categories were compared by the Chi-square test. A two-sided P value of 0.05 or less was considered significant. All analyses were performed using SPSS software.
Results
Graft characteristics
The median CD34 ϩ cell number transplanted was 3. 
Engraftment
The median time to recover an absolute neutrophil count (ANC) of 0.5 ϫ 10 9 /l was 10 days (range 5-15), while the time to platelet transfusion independence was 11 days (range 3-42) after transplant. When comparing the median time to neutrophil recovery ( Table 2) there was a significant difference between the different groups (low vs intermediate, P ϭ 0.0025, intermediate vs high, P ϭ 0.047). Platelet transfusion dependence was significantly longer for patients receiving less than 2 ϫ 10 6 /kg CD34 ϩ cells compared to the intermediate CD34 group (P ϭ 0.0025, Table 3 ) with no significant difference between the intermediate and high CD34 groups. Patients in the low CD34 group received significantly more platelet transfusions than patients from the intermediate group (9 vs 5 units, P ϭ 0.018), while the difference between the intermediate and the high CD34 group failed to reach statistical significance (5 vs 5 units, P ϭ 0.09). There was no statistically significant difference for red cell transfusions (Table 3) .
Febrile complications
Of all patients 13.4% experienced no febrile episodes, 46.4% had 1-3 days of fever Ͼ38°C while 40.2% had more than 3 febrile days. The median duration of fever was 3 days (range 0-22). Positive blood cultures were obtained in 74 cases, showing coagulase-negative Staphylococci (n ϭ 48), Enterococci (n ϭ 11), Strep viridans (n ϭ 9), Pseudomonas aeruginosa (n ϭ 5), E coli (n ϭ 4), Stenotrophomonas maltophiliae (n ϭ 3), Serratia marcescens (n ϭ 2), Peptococcaceae (n ϭ 1), Strep oralis (n ϭ 1), Proteus mirabilis (n ϭ 1), Klebsiella pneum (n ϭ 1) or Candida albicans (n ϭ 1). There was an inverse relation between duration of fever and CD34 ϩ cell dose (Figure 1 ). Compar- ing the different groups (Table 4) there was a significant reduction in the incidence (92.1% vs 78.8%, P ϭ 0.039) and the median duration of neutropenic fever from 3.5 days in the intermediate group to 1 day in the high CD34 group, respectively (P ϭ 0.0025). This was paralleled by the median duration of empirical antibiotic treatment, being 10 days in the intermediate group and 7 days in the high CD34 group (P ϭ 0.038). The difference in the incidence of positive blood cultures (52.6% in the intermediate CD34 group and 33.3% in the high CD34 group, P ϭ 0.064) failed to reach significance. No significant effect on the duration of fever was found for age (below vs above the median, P ϭ 0.67), diagnosis (lymphoma vs solid tumour vs myeloma/leukaemia, P ϭ 0.54), mobilisation regimen (G-CSF vs chemotherapy with G-CSF, P ϭ 0.53) or conditioning regimen (TBI-containing vs others, P ϭ 0.20). The effect of neutrophil recovery on fever duration also failed to reach significance (below vs above the median, P ϭ 0.057).
Discussion
The use of autologous stem cell transplantation has entered routine practice for the treatment of a variety of malignant and non-malignant disorders as seen in the list of indications recently published by the European Group for Blood and Marrow Transplantation (EBMT). 5 Therefore, safety and cost considerations have become increasingly important. Several groups have put forward standards for peripheral stem cell transplants, including threshold values for the number of transplanted CD34 ϩ cells and a level of at least 2 ϫ 10 6 /kg has generally been accepted. However several groups have demonstrated beneficial effects of using more than 2 ϫ 10 6 /kg CD34 ϩ cells for transplantation. In a study by Kiss /kg CD34 ϩ cells: using the higher CD34 ϩ cell dose led to a significant reduction in the duration of neutropenia, thrombocytopenia and platelet transfusion requirement. There was also a non-significant trend for reduced antibiotic treatment in the higher CD34 ϩ group, while the incidence of infections was similar. It has to be noted that a threshold dose of 15 ϫ 10 6 /kg is rather high and may not be achievable in many patients. From our data from 127 transplants only three patients would fit into that group.
In order to evaluate the impact of the stem cell dose on post-transplant parameters in our patients we performed a retrospective analysis of 127 autologous peripheral stem cell transplants in our centre. Our data show a significant reduction in the length of febrile neutropenia and systemic antibiotic treatment when the number of transplanted stem cells was at least 5 ϫ 10 6 /kg rather than the generally accepted minimum of 2 ϫ 10 6 /kg. To our knowledge this is the first time that a significant effect of CD34 ϩ cell dose on febrile neutropenia after autologous PBSCT has been demonstrated. The fact that we did not note a significant reduction in platelet transfusion requirements in the high CD34 group may be due to our (now abandoned) policy to keep platelet counts Ͼ40 ϫ 10 9 /l rather than the generally accepted threshold of 10-20 ϫ 10 9 /l. [7] [8] [9] When looking for an explanation for the observed shortening of neutropenic fever with higher CD34 ϩ cell doses it is obvious that the effect of neutrophil recovery should be considered. In fact, we found a significant acceleration of ANC recovery between high and intermediate CD34 ϩ groups. However, when we assessed the effect of neutrophil recovery on duration of fever directly we did not find a significant difference. Thus it remains questionable whether a faster ANC recovery can fully explain the reduction in neutropenic fever with higher CD34 ϩ cell doses. In a very recent large single centre study 10 it has been shown that neutrophil and platelet recovery was not only affected by the CD34 ϩ cell dose but, at least on univariate analysis, also by other variables such as diagnosis, mobilisation or conditioning regimen. We analysed whether any of these parameters had an impact on the duration of neutropenic fever in our patients but failed to detect any significant effect.
Another possible explanation for a reduction in febrile complications after PBSCT may be an increased number of immunocompetent cells transfused in parallel to the CD34 ϩ cells. CD8 ϩ T cells and natural killer cells recover rapidly and early after autologous PBSCT 11 an effect which seems to be delayed after CD34 ϩ selected transplants (Scheid et al, manuscript in preparation), indicating a role of transfused non-haematopoietic cells in the early recovery of lymphoid cells. As lymphocytes and monocytes comprise the vast majority of cells in unselected PBSC grafts we compared the number of PBSC bags infused at transplantation between the different groups. The high CD34 group received a similar number of bags as the intermediate group (see Table 2 ), therefore, the number of lymphocytes and monocytes transfused can not account for the reduction in fever in the high CD34 group.
Another consideration is the potential tumour cell contamination of PBSC grafts, as tumour cells have been shown to be mobilised in the setting of stem cell mobilisation. However, we did not observe any difference in early relapse rates up to 6 months after transplant between the intermediate and high CD34 groups (17% vs 16%).
In summary, our data show a clear benefit of infusing at least 5 ϫ 10 6 /kg CD34 ϩ cells for autologous PBSCT, leading to a reduction of febrile neutropenia and antibiotic treatment after transplantation. This should help to increase the safety and reduce the cost of this widely used therapeutic modality. We recommend that more than the threshold number of 2 ϫ 10 6 /kg CD34 ϩ cells are collected especially in those patients with a good mobilisation capacity.
